Division of Hematology and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy.
Bone Marrow Transplant. 2010 Nov;45(11):1607-10. doi: 10.1038/bmt.2010.19. Epub 2010 Feb 22.
We studied killer-cell Ig-like receptor (KIR)/natural killer (NK)-cell group-2-Ag repertoires on donor-derived NK cells in 28 patients after haploidentical SCT in the first 6 months after SCT and correlated results with EFS. The reconstitution hierarchy of potentially alloreactive, single KIR+ NK cells was the following: HLA-C1 binding>HLA-Bw4 binding>HLA-C2 binding. The differences in reconstitution kinetics of the three potentially alloreactive NK cell subsets prompted an updated analysis of EFS in AML patients transplanted from haploidentical donors in our center. This analysis showed that in haploidentical transplantation for AML, HLA-C group 1 mismatching in the graft vs host direction not only provides a survival advantage over non-NK-alloreactive (KIR ligand-matched) transplants (5-year EFS 67±10% vs 17±5%) but, indeed, also provides the best EFS compared with C2 (35±10%) or Bw4 KIR ligand mismatches (44±17%). In conclusion, we show that the kinetics with which single KIR-expressing NK cells are generated after haploidentical SCT differ between individual KIR receptors and seem to influence survival after haploidentical SCT.
我们研究了 28 例接受半相合 SCT 后前 6 个月供体来源 NK 细胞上的杀伤细胞免疫球蛋白样受体(KIR)/自然杀伤(NK)细胞组 2-Ag 谱,并将结果与 EFS 相关联。潜在同种反应性单 KIR+NK 细胞的重建层次如下:HLA-C1 结合>HLA-Bw4 结合>HLA-C2 结合。三种潜在同种反应性 NK 细胞亚群重建动力学的差异促使我们对本中心接受半相合供体移植的 AML 患者的 EFS 进行了更新分析。该分析表明,在 AML 的半相合移植中,移植物抗宿主方向的 HLA-C 组 1 错配不仅提供了比非 NK 同种反应性(KIR 配体匹配)移植(5 年 EFS 为 67±10%比 17±5%)更长的生存优势,而且与 C2(35±10%)或 Bw4 KIR 配体错配(44±17%)相比,确实提供了最佳的 EFS。总之,我们表明,半相合 SCT 后单 KIR 表达 NK 细胞的生成动力学因个体 KIR 受体而异,并且似乎影响半相合 SCT 后的生存。